NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – What’s Next?

NKGen Biotech, Inc. (NYSE:NKGN) dropped 2.3% on Monday . The stock traded as low as $0.67 and last traded at $0.70. Approximately 466,789 shares were traded during trading, a decline of 72% from the average daily volume of 1,656,951 shares. The stock had previously closed at $0.71.

NKGen Biotech Stock Performance

The company’s fifty day moving average price is $0.42 and its two-hundred day moving average price is $0.70. The firm has a market capitalization of $24.65 million, a PE ratio of -0.14 and a beta of 0.77.

Hedge Funds Weigh In On NKGen Biotech

An institutional investor recently raised its position in NKGen Biotech stock. Polar Asset Management Partners Inc. grew its position in shares of NKGen Biotech, Inc. (NYSE:NKGN) by 9.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,181,872 shares of the company’s stock after purchasing an additional 101,872 shares during the quarter. Polar Asset Management Partners Inc. owned 3.34% of NKGen Biotech worth $447,000 as of its most recent filing with the SEC. 76.17% of the stock is owned by institutional investors.

NKGen Biotech Company Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.